

**von Willebrand Factor
As a marker of Endothelial
Dysfunction in Acute Coronary Syndrome**

Thesis

Submitted for partial Fulfillment of M.Sc. Degree
in **Clinical and Chemical Pathology**

By

Heba Mostafa Abd-Elkader Tork

(M.B.B.CH)

Ain Shams University

Supervised by

Professor/ Nevine Ahmed Kassim

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Professor/Amal Abd-Elhamid Mohamed

*Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University*

Doctor/Deena Mohamed Mohamed Habashy

*Lecturer of clinical and chemical Pathology
Faculty of Medicine, Ain Shams University*

***Faculty of Medicine
Ain Shams University***

2011

عامل فون ويلبراند كعلامة للاختلال الوظيفي للوعاء الدموي في أمراض الشرايين التاجية الحادة

الرسالة

توطئة للحصول على درجة الماجستير في الباثولوجيا الإكلينيكية والكيميائية

مقدمة من

هبة مصطفى عبد القادر ترك / طبيب

كلية الطب جامعة عين شمس - و الجراحة بكالوريوس الطب

تحت إشراف

الأستاذ الدكتور / نيفين أحمد قاسم

والكيميائية أستاذ الباثولوجيا الإكلينيكية

جامعة عين شمس - كلية الطب

الدكتور / آمال عبد الحميد محمد

والكيميائية أستاذ الباثولوجيا الإكلينيكية

جامعة عين شمس - كلية الطب

محمد محمد حبشي دينا/ الدكتور

مدرس الباثولوجيا الإكلينيكية والكيميائية

جامعة عين شمس - كلية الطب

- جامعة عين شمس كلية الطب

٢٠١١

Summary and Conclusion

Under physiological conditions, the vascular endothelium produces many substances that contribute importantly to hemostasis, fibrinolysis, and regulation of vessel tone and permeability. One such substance is glycoprotein von Willebrand factor (vWf), which is almost exclusively produced by the endothelium, and thus is a marker of endothelial activation or dysfunction. vWf mediates platelet adhesion to the vascular wall, platelet aggregation and serves as a plasma carrier for factor VIII, stabilizing it in the circulation. Since almost all acute coronary syndromes (ACSs) result from thrombus formation in preexisting atherosclerosis, and given the key role of vWf in arterial thrombus formation, this biomarker attracted considerable interest as a predictor of cardiovascular disease (CVD).

Previously published studies suggest that there is a weak association between vWf plasma levels and risk of coronary heart disease (CHD) in general population, but its predictive value significantly rises in patients with preexisting vascular disease, diabetics, and the elderly. It was noticed that vWf rises during the course of ACSs, and it is thought that vWf is not only a marker, but also a mediator in the pathogenesis of myocardial infarction (MI). Although a number of studies pointed out the prognostic value of vWf, there is still a long way to go before plasma vWf levels can be used as a predictor of cardiovascular disease in clinical practice.

In this regards, our study aimed to evaluate the role of vWF as marker for prognosis in association with other inflammatory marker such as hs-CRP in patients with acute coronary syndrome.

LIST OF CONTENTS

❖ List of abbreviations	--
❖ List of figures	--
❖ List of tables	--
❖ Introduction & aim of work	1
❖ Review Of Literature	
I- Endothelium	4
A-Endothelial physiology	4
B- Anti thrombotic function of endothelium	4
C- Dysfunction of endothelium	7
(Inflammation and thrombosis)	
D- Plasma markers associated with endothelial damage	
1-von Willebrand Factor	8
2-Soluble thrombomodulin	8
3- E-selectin	9
4- Nitric oxide	9
5- Endothelin	10
II- von Willebrand Factor	11
A-Definition	11
B- Structure	12
• Functional domains of vWF	12
C- Biosynthesis of vWF	13
D- Storage and secretion	15
E- Factors affecting vWF level	15
F- Physiological function of vWF	15
1-vWF binding of vessel wall	15
2- platelet adhesion to connective tissue	16
3- vWF important in thrombus formation	16
4- vWF binding to heparin	20
5- Stabilization of blood coagulation FVIII	20
6- vWF as acute phase reactant	20

LIST OF CONTENTS (Cont.)

G- Elevated vWF level in other diseases	21
1- vWF and conditions associated with thromboembolism	21
• Atrial fibrillation	21
• Left ventricular dysfunction	21
• Cerebrovascular disease	22
• Venous thrombosis	22
2- vWF and pulmonary vascular disease	23
3- vWF and diabetes	23
4- vWF and hypertension	23
5- vWF and inflammatory vascular disease	24
6- vWF and homocysteinuria	25
H- vWF and acute coronary syndrome	26
I- vWF and percutaneous intervention	26
K- vWF and thrombolysis	27
L- von Willebrand disease	28
1- Background	28
2- Pathophysiology	29
3- vWD types	29
M- Laboratory identification and clinical evaluation of vWF	30
• Indication for evaluation of persons for possible vWD	30
• Laboratory assay	31
1- Activated Partial thromboplastin time	31
2- Skin bleeding time	32
3- Ristocetin co-factor activity	32
4- Ristocetin-induced platelet aggregation(RIPA)	33
5- von Willebrand immunoassay	34
6- von Willebrand collagen binding activity	34
7- Platelets function analyzer PFA 100—closure time	35

LIST OF CONTENTS (Cont.)

8-F VIII coagulant activity	36
9-Assay the ability of vWF to bind F VIII	36
10-Multimer assay	36
11-Assay for detecting vWF antibody	38
III- Acute coronary syndrome	39
a) Definition of Acute Coronary Syndrome	39
b) Classification of Acute coronary Syndrome ...	40
c) Epidemiology of Acute Coronary Syndrome ..	41
d) Normal Physiology of Coronary Blood Flow ..	42
e) Pathophysiology of Acute Coronary Syndrome	44
• Development and Progression of Atherosclerosis	46
• Development of Acute Coronary Syndrome	46
f) Risk factors of Acute Coronary Syndrome	52
• Age	52
• Gender	52
• Genetic Predisposition and Family History	53
• Smoking	53
• Obesity	54
• Sedentary Life and Physical Exercise	54
• Hypertension	54
• Dyslipidemia	55
• Diabetes Mellitus and Metabolic Syndrome ...	57
• Infections	58
• Mental Depression and Stress	58
• Alcohol intake	58
• Novel Risk Factors	58
g) Diagnosis of Acute Coronary Syndrome	59
A) Clinical Presentation	59
B) Physical Examination	60
C) ECG Findings in Patients with ACS	60
D) Radiological Diagnosis of ACS	60

LIST OF CONTENTS (Cont.)

h) Laboratory Investigations of ACS	61
8) Risk Stratification of Patients with ACS	65
9) Prognosis of Patients with ACS	68
❖ Subjects and methods	69
❖ Results	78
❖ Discussion	92
❖ Summary and conclusion	99
❖ Recommendations	102
❖ References	103
❖ Arabic summary	--

List of Abbreviations

ACS	Acute Coronary Syndrome
ADMTS13	A Disintegrin and Metallo- proteinase with Thrombospondin type 1 repeats-13
AMI	Acute Myocardial Infarction
APP	Acute Phase Protein
APR	Acute Phase Reaction
APTT	Activated Partial Thromboplastin Time
AUC	Area Under Curve
CAD	Coronary Artery Disease
CK	Creatine Kinase
CK MB	Creatine Kinase MB fraction
CRP	C- Reactive Protein
CtnI	Cardiac Troponin I
ECG	ElectroCardioGram
ED	Emergency Department
ELISA	Enzyme Linked Immunosorbent Assay
FV_{III}	Factor V _{III}
GPIb	Glycoprotein Ib
HDL-C	High Density Lipoprotein – Cholesterol
hs CRP	High sensitivity C-Reactive Protein
ICAM	Intracellular Adhesion Molecules
IL-6	Interleukin – 6
LD	Lactate Dehydrogenase
MeTS	Metabolic Syndrome
NADH	Reduced β -nicotinamide adenine dinucleotide
Ox-LDL	Oxidized –LDL
PCI	Percutaneous Coronary Intervention
PDGF	Platelet Derived Growth Factor
PFA100	Platelet Function Analyser 100
POCT	Point Of Care Testing
ROS	Reactive Oxygen Species

List of Abbreviations (Cont.)

STEMI	ST Elevation Myocardial Infarction
SBT	Skin Bleeding Test
TFPI	Tissue Factor Plasminogen Inhibitor
TF	Tissue Factor
TGF	Transforming Growth Factor
TM	Thrombomodulin
TNF	Tumor Necrosis Factor
t-PA	Tissue Plasminogen Activator
TIMI	Thrombolysis In Myocardial Infarction
UA	Unstable Angina
VCAM	Vascular Cell Adhesion Molecules
vWD	von Willebrand Disease
Vwf	von Willebrand Factor
vWF: Rco	Ristocetin cofactor activity assay
vWF:Ag	Antigen of von Willebrand Factor
vWF:CB	von Willebrand Factor Collagen Binding
vWF:PB	vWF Platelet-Binding
VSMCs	Vascular Smooth Muscle Cells

LIST OF FIGURES

Fig.	Subject	Page
1	Structure and domains of von Willebrand factor (vWF).	11
2	Pathways and modes of vWF secretion from endothelial cells.	14
3	Diagram of the roles of von Willebrand Factor in platelet adhesion to the damaged wall of the blood vessel and subsequent platelet aggregation.	16
4	The role of vWF in thrombus formation.	19
5	Analysis of von Willebrand Factor multimers.	37
6	Classification of acute coronary syndrome	41
7	Normal structure of the wall of healthy artery.	43
8	Fatty streak formation.	45
9	Formation of an advanced, complicated lesion of atherosclerosis.	46
10	Comparison between vWF level (before and after therapy) and hs-CRP level (before and after therapy) in all studied group.	88
11	The difference in the level of vWF and hs-CRP in different methods of treatment.	89
12	No correlation detected between vWF after therapy and hs-CRP after therapy.	90
13	There is a correlation between vWF level before therapy and vWF level after therapy.	90
14	ROC curve showing the best cutt off of vWF level to determine its prognostic value in acute coronary syndrome.	91

LIST OF TABLES

Table	Subject	Page
1	Autocrine and paracrine substance released from endothelium	5
2	Regulation of hemostasis and thrombosis by endothelium	6
3	The relationship between risk of developing of CAD and LDL, LDL-C, HDL-C and total cholesterol.	56
4	Biomarkers of ACS	62
5	Biochemical markers of ACS	63
6	Risk stratification to determine the likelihood of ACS	67
7	Demographic data and clinical characteristics of patients included in this study	81
8	Statistical comparison between vWF (before and after therapy) and hs-CRP (before and after therapy) in all studied groups	82
9	Statistical comparison of vWF (before , after)& hs-CRP (before ,after) in different patients' group	83
10	Comparison between STEMI and NSTEMI regarding all risk factors	84
11	Statistical comparison between different methods of treatment regarding vWF &hs-CRP levels after therapy	85
12	Correlation of vWF levels and hs-CRP levels before therapy vs after therapy	86
13	Correlation between vWF (before, after),hs-CRP (before, after) and CPK	86
14	Correlation of vWF (before, after), hs-CRP (before, after) and improvement	87
15	Correlation of risk factors to improvement	87

Introduction

It has been known that alterations in blood flow vascular wall, and blood components, the so-called **Virchow's triad**, may progressively lead to thrombus formation. Recently, a more understanding of the complex interactions among the vascular endothelium, platelet adhesion, activation, aggregation, and clotting factor activation are involved in this process (*Alexander et al., 2008*).

Under physiological conditions, the vascular endothelium produces many substances that contribute importantly to hemostasis, fibrinolysis, and regulation of vessel tone and permeability. One such substance is the multimeric glycoprotein von Willebrand factor (vWF), which is produced almost exclusively by endothelial cells (*Hollestella et al., 2001*).

Plasma levels of vWF are raised in different states of endothelial damage and have therefore been proposed as useful markers of endothelial dysfunction. Along this line, blockade of nitric oxide enhances the stimulated release of vWF in humans. Furthermore, vWF plays a crucial role in platelet adhesion and aggregation under high shear condition (*Pernerstorfer et al., 2000*).

Finally, vWF supports the third component of Virchow's triad, clotting factor activation, by acting as a carrier protein and stabilizer for factor VIII (*Alexander et al., 2008*).

Almost all **Acute Coronary Syndromes (ACS)** result from thrombus formation in preexisting coronary atherosclerosis. As a result of plaque rupture and exposure of prothrombotic subendothelial matrix, local thrombus formation occurs, which subsequently leads to coronary artery occlusion and **Acute Myocardial Infarction (AMI)**.

The presence of vWF has been shown to play a pivotal role in platelet aggregation at sites of high shear, eg, at the sites of lesions in the coronary arteries (*Fredrickson et al., 1998*).

Accordingly, vWF may be a marker of cardiovascular risk, and its plasma level with other inflammatory markers such as high sensitivity C -Reactive Protein (hs-CRP) may increase in patients with ACS. In addition vWF may play a role in thrombogenesis. therapies that specifically inhibit vWF are of particular interest as potential new antiplatelet drug (*Alexander et al., 2008*).

C- Reactive Protein (CRP) is a trace protein in the circulation of healthy subjects, concentration can increase 100-fold or more in response to injury, infection, or inflammation. Moderately increased plasma CRP concentrations are found in smokers and under conditions of atherosclerosis, psychological stress, diabetes, and obesity, and in the elderly (*Cao et al., 2003*).

Increased biomarkers of inflammation, including hs-CRP, have been associated with increased stroke risk and further coronary events as well as an increased rate of atherosclerosis progression in the carotid and coronary vessels. The variation in hs-CRP can be affected by genetic factors, diet, exercise, and smoking cessation (*Ridker et al., 2008*).

CRP is associated with endothelial cell dysfunction and progression of atherosclerosis, possibly by decreasing nitric oxide synthesis (*Libby et al., 2003*). This suggests that high **CRP** plasma concentrations and the extent of its deposition in the atherosclerotic plaque are associated with plaque vulnerability and the occurrence of acute thrombotic events (*Pepys et al., 2003*).

Aim of The Work

This work aims to assessment of vWF in Acute Coronary Syndromes and measurement of hs-CRP level in ACS and its correlation to vWF level.

A-Endothelial cell Physiology:

The inner lining (intima) of all blood vessels consists of a monolayer of flattened, orthogonal cells referred to as the endothelium, positioned on the internal elastic lamina. The vascular endothelium is not just a cell lining, but plays an active role via various mediators in the equilibrium of haemostasis and fibrinolysis (*Pusztaszeri et al., 2005*).

Normal functions of endothelial cells include mediation of coagulation, platelet adhesion, immune function, control of volume and electrolyte content of the intravascular and extravascular spaces. Endothelial dysfunction can result from and/or contribute to several disease processes, as occurs in septic shock, hypertension, hypercholesterolaemia, diabetes as well from environmental factors, such as from smoking tobacco products and exposure to air pollution (*Dean field et al., 2005*).

B-Antithrombotic function of endothelium:

Endothelium produces many substances (*Table 1*) with autocrine and paracrine activity (*Vermas et al., 2002*). Factors which are regulated by the endothelium and take active part in hemostasis and thrombosis are shown in (*Table 2*). One of the most important function of endothelial cells is the prevention of non-physiological activation of blood coagulation resulting in thrombosis. This activity is mediated by the negative charge of the endothelium provided by surface expression of heparan sulfate proteoglycans and the secretion of prostacyclin, nitric oxide (NO), tissue factor pathway inhibitor (TFPI) and tissue plasminogen activator (t-PA). Endothelial expression of thrombomodulin (TM), which binds to thrombin and activates anticoagulant protein C, plays a very important antithrombotic role. Endothelial damage triggers thrombus formation due to decreased antithrombotic potential, expression of tissue factor